Pertuzumab, trastuzumab, and hyaluronidase-zzxf (Subcutaneous)
Medically reviewed by Drugs.com. Last updated on May 18, 2022.
CardiomyopathyPertuzumab/trastuzumab/hyaluronidase-zzxf administration can result in subclinical and clinical cardiac failure manifesting as congesting heart failure, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue pertuzumab/trastuzumab/hyaluronidase-zzxf for cardiomyopathy.Embryo-fetal ToxicityExposure to pertuzumab/trastuzumab/hyaluronidase-zzxf can result in embryo-fetal death and birth defects. Advise patients of these risks and the need for effective contraception.Pulmonary ToxicityDiscontinue pertuzumab/trastuzumab/hyaluronidase-zzxf for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome .
Commonly used brand name(s)
In the U.S.
- Phesgo
Available Dosage Forms:
- Solution
Therapeutic Class: Antineoplastic Agent
Pharmacologic Class: Monoclonal Antibody
Uses for pertuzumab, trastuzumab, and hyaluronidase-zzxf
Pertuzumab, trastuzumab, and hyaluronidase-zzxf combination injection is used first together with other cancer medicines to treat HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 centimeters in diameter or node positive) as part of a complete treatment plan for early breast cancer. It is also used after an initial treatment plan to treat HER2-positive early breast cancer which has a high risk of occurring again.
Pertuzumab, trastuzumab, and hyaluronidase-zzxf combination injection is also used together with docetaxel to treat HER2-positive metastatic (cancer that has spread) breast cancer in patients who have not previously received cancer treatment.
Pertuzumab, trastuzumab, and hyaluronidase-zzxf combination prevents the growth of some tumors that produce extra amounts of a certain substance known as the HER2 protein. It should only be used in patients whose tumors have been shown to produce extra amounts of this protein (HER2 overexpression).
Pertuzumab, trastuzumab, and hyaluronidase-zzxf is to be given only by or under the direct supervision of your doctor.
Before using pertuzumab, trastuzumab, and hyaluronidase-zzxf
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For pertuzumab, trastuzumab, and hyaluronidase-zzxf, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to pertuzumab, trastuzumab, and hyaluronidase-zzxf or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of pertuzumab, trastuzumab, and hyaluronidase-zzxf combination injection in the pediatric population. Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the us..
